Questions.info

5-FU practice questions: five clinical decisions

Fluorouracil forms FdUMP, which inhibits thymidylate synthase; FUTP, incorporated into RNA; and FdUTP, incorporated into DNA.

Fluorouracil (5-FU) practice questions test more than a drug’s mechanism. Safe reasoning connects DPYD testing, leucovorin’s effect, a correctly interpreted infusion order, early severe toxicity and regimen-specific treatment-duration evidence. This five-question case lets you work through those decisions in sequence.

Follow one patient from planning to urgent reassessment

Maya is a fictional 58-year-old adult recovering from complete resection of pT3N1a colon cancer. Her oncology team is considering adjuvant treatment. She has a documented body surface area of 1.75 m². Treatment is planned for the following week; there is no immediate-treatment requirement.

At the planning visit, the team discusses fluorouracil, leucovorin and oxaliplatin, commonly grouped as FOLFOX. CAPOX uses capecitabine with oxaliplatin instead. Maya asks whether an oral fluoropyrimidine changes the need for safety screening and whether a shorter course would reduce neuropathy. These questions belong in the treatment discussion before the first cycle, rather than after an adverse effect appears.

The team obtains pretreatment DPYD testing. A limited variant panel identifies none of the variants it tests. After clinical assessment, the team proceeds with a fluorouracil-containing regimen. The fictional order specifies a separate bolus and 2400 mg/m² as the total continuous-infusion dose over 46 hours. For the calculation below, use the supplied BSA and do not include the bolus.

Thirty hours after the infusion ends, Maya develops unusually severe mouth sores, profuse diarrhea and new confusion. Emergency assessment also identifies profound neutropenia. She is already being evaluated in hospital; the team is considering early severe fluoropyrimidine toxicity while investigating other causes and checking the medication-delivery record.

Answer these five 5-FU practice questions

Work through the questions in order. Each has one best answer in the linked case set, with an explanation for every choice.

  1. Before treatment: When immediate treatment is unnecessary, what pretreatment testing action does the current U.S. fluorouracil label direct?
  2. At the regimen check: Why is leucovorin given with fluorouracil, and what interaction with thymidylate synthase explains that role?
  3. At the dose check: With BSA 1.75 m² and an order for 2400 mg/m² as the total 46-hour infusion dose, how many milligrams belong in the infusion, excluding the bolus?
  4. At urgent reassessment: With unusually severe gastrointestinal toxicity, neutropenia and confusion 30 hours after the infusion ends, which emergency antidote warrants urgent consideration alongside supportive care?
  5. At the earlier duration discussion: What is the most accurate way to explain IDEA evidence for a pT3N1a patient when comparing FOLFOX and CAPOX duration?

Use four distinctions to check your reasoning

DPYD testing reduces risk; a negative panel does not guarantee safety

DPYD is the gene that encodes dihydropyrimidine dehydrogenase, or DPD. DPD catabolizes most fluorouracil. Reduced enzyme activity can increase the risk of serious or fatal toxicity, including severe mucositis, diarrhea, neutropenia and neurologic effects.

The fluorouracil prescribing information, revised January 2026, directs testing for DPYD variants before treatment unless immediate treatment is necessary. It also says that tests differ in design and that serious adverse reactions can occur even when no variant is identified. Maya’s negative limited panel therefore cannot explain away the later emergency.

Capecitabine is converted to fluorouracil. Its October 2025 Xeloda label also directs pretreatment testing unless immediate treatment is necessary. Oral administration does not bypass the DPD-related risk. Neither the fictional symptoms nor a single negative panel establishes Maya’s actual enzyme activity; the clinical team must investigate.

Leucovorin potentiation is different from antidote treatment

Fluorouracil produces several active metabolites. FdUMP inhibits thymidylate synthase; FUTP is incorporated into RNA; FdUTP is incorporated into DNA. Bolus and continuous infusion differ in exposure and toxicity patterns, but “bolus affects only RNA” and “infusion affects only DNA” are too absolute.

Leucovorin supplies reduced folate that stabilizes FdUMP binding to thymidylate synthase. The September 2025 leucovorin label’s Clinical Pharmacology section explains that it can enhance both the therapeutic and toxic effects of fluorouracil. It is not the emergency fluoropyrimidine antidote, and stabilized inhibition should not be described as permanently disabling every future enzyme molecule in a cell.

A total infusion dose is not a daily dose

The order’s units tell you which calculation to perform. First identify whether the mg/m² amount is a total dose or a dose per day. Multiply the stated total mg/m² dose by BSA once. The 46-hour duration determines delivery time; it does not turn that total into two daily doses.

A separate bolus is a separate order component. If a later question asks for a pump rate, you also need the verified prepared volume and intended duration. An excessive infusion rate can constitute a fluorouracil overdose even when the total amount matches the original order, as described in the Vistogard label’s Clinical Studies section.

Antidote timing and IDEA endpoints need precise wording

Uridine triacetate is labeled for fluorouracil or capecitabine overdose regardless of symptoms, and for qualifying early-onset severe or life-threatening toxicity within 96 hours after administration ends. The October 2023 Vistogard prescribing information says to administer it as soon as possible when indicated. The window is not a reason to wait. Safety and efficacy of starting after 96 hours have not been established; that is not proof of absolute ineffectiveness after hour 96.

For treatment duration, the IDEA final analysis, published in Lancet Oncology in December 2020, distinguishes regimen, risk group and endpoint. The original pooled analysis did not establish overall noninferiority for three-year disease-free survival across both regimens. The final overall-survival analysis also did not confirm noninferiority after multiplicity adjustment, despite a small absolute difference in five-year overall survival.

The evidence supports discussion of shorter CAPOX treatment, with lower-risk disease defined in IDEA as T1–3/N1. It does not supply a universal three-month FOLFOX rule. CAPOX versus FOLFOX was not randomly assigned, so IDEA is not a randomized head-to-head proof that one regimen is superior. Reducing cumulative oxaliplatin sensory neurotoxicity is an important trade-off, not a guarantee of avoiding permanent injury.

Put your decisions to the test

Answer the five case questions in Questions.info. Choose one answer for each decision, then compare your reasoning with the choice-by-choice explanations and dated references.

This case was inspired by The 70-Year-Old Drug That Still Holds Cancer’s Feet to the Fire, published on obaid.info on September 26, 2026. The patient, timeline, questions and explanations are original; the clinical teaching points above are referenced to drug labels and the IDEA publication.

This is an educational case, not patient-specific clinical advice. People receiving chemotherapy should follow their oncology team’s instructions and seek urgent care for severe symptoms.

Keep your next study read close

Opt in by email, or follow new articles in your feed reader. Email notifications are not automated yet.

Email subscriptionFollow the RSS feed